全球止咳藥市場規模、佔有率、趨勢及成長分析報告（2026-2034）

預計止咳藥市場將從 2025 年的 17.3 億美元成長到 2034 年的 25.8 億美元，2026 年至 2034 年的複合年成長率為 4.59%。

由於呼吸道疾病和季節性疾病的日益普遍，導致持續咳嗽，全球止咳藥市場正穩定成長。止咳藥，俗稱“咳嗽藥”，透過作用於腦部和喉嚨的咳嗽反射來緩解咳嗽。這些藥物廣泛用於治療感冒、流感、支氣管炎和其他呼吸道感染疾病的相關症狀。人們對呼吸系統健康的日益關注也推動了對這些藥物需求的成長。

市場成長受多種因素驅動，包括呼吸道感染疾病上升和環境污染加劇。氣候變遷和都市區空氣污染加劇了呼吸道疾病，導致止咳藥使用量增加。此外，處方藥和非處方藥的普及也使消費者更容易獲得治療選擇。製藥公司也正在研發改良配方，以更快地緩解症狀並延長藥效。

鑑於全球健康意識的持續提升，止咳藥市場前景光明。製劑創新和聯合治療可望提高呼吸道症狀的治療效果。新興市場藥品分銷網路的拓展和醫療服務可近性的改善預計也將推動市場成長。由於呼吸系統疾病在全球範圍內仍然普遍存在，對有效止咳藥的需求預計將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球止咳藥市場：依藥物類型分類

• 市場分析、洞察與預測
• Benzonatate
• Dextromethorphan

第5章 全球止咳藥市場：依藥物類別分類

• 市場分析、洞察與預測
• 中樞鎮咳藥
• 周邊促效劑
• 其他

第6章：全球止咳藥市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 吸入劑
• 其他

第7章 全球止咳藥市場：以劑型分類

• 市場分析、洞察與預測
• 糖漿
• 藥片
• 其他

第8章 全球止咳藥市場：依適應症分類

• 市場分析、洞察與預測
• 感冒症狀
• 疼痛
• 咳嗽
• 其他

第9章 全球止咳藥市場：依產品類型分類

• 市場分析、洞察與預測
• 非處方藥
• 處方藥

第10章 全球止咳藥市場：依年齡層別分類

• 市場分析、洞察與預測
• 兒童
• 成人
• 老年人

第11章 全球止咳藥市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 專科診所
• 居家照護
• 其他

第12章 全球止咳藥市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

第13章 全球止咳藥市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第14章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第15章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Novartis AG
  • GlaxoSmithKline Plc
  • Sanofi
  • Johnson & Johnson Private Limited
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Mylan NV
  • AstraZeneca
  • Bayer AG
  • Cipla Inc
  • Aurobindo Pharma
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals LLC

The Antitussive Drugs Market size is expected to reach USD 2.58 Billion in 2034 from USD 1.73 Billion (2025) growing at a CAGR of 4.59% during 2026-2034.

The global antitussive drugs market has grown steadily due to the increasing prevalence of respiratory conditions and seasonal illnesses that cause persistent coughing. Antitussive drugs, commonly known as cough suppressants, are used to reduce coughing by acting on the cough reflex in the brain or throat. These medications are widely used in treating symptoms associated with colds, flu, bronchitis, and other respiratory infections. Growing awareness about respiratory health has contributed to increased demand for these medications.

Market growth is driven by several factors, including the rising incidence of respiratory infections and environmental pollution. Changing weather conditions and urban air pollution can aggravate respiratory conditions, leading to increased use of cough suppressants. In addition, the availability of both prescription and over-the-counter antitussive medications has expanded consumer access to treatment options. Pharmaceutical companies are also developing improved formulations that provide faster symptom relief and longer-lasting effects.

The future of the antitussive drugs market appears positive as healthcare awareness continues to increase worldwide. Innovations in drug formulations and combination therapies may enhance treatment effectiveness for respiratory symptoms. Expanding pharmaceutical distribution networks and growing access to healthcare services in emerging markets are also expected to support market growth. As respiratory illnesses remain common globally, demand for effective cough suppression treatments is likely to continue.

MARKET SEGMENTATION

By Drug

• Benzonatate
• Dextromethorphan

By Drug Class

• Centrally Acting Drugs
• Peripherally Acting Drugs
• Others

By Route of Administration

• Oral
• Inhalational
• Others

By Dosage Form

• Syrup
• Tablet
• Others

By Indication

• Cold Symptoms
• Pain
• Cough
• Others

By Product Type

• Over-The-counter (OTC)
• Prescription Drug

By Age Group

• Pediatric
• Adult
• Geriatric

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Pfizer Inc, Novartis AG, GlaxoSmithKline plc, Sanofi, Johnson Johnson Private Limited, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan NV, AstraZeneca, Bayer AG, Cipla Inc, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Benzonatate Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dextromethorphan Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Centrally Acting Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Peripherally Acting Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTITUSSIVE DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Inhalational Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Dosage Form
• 7.2. Syrup Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Tablet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTITUSSIVE DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Indication
• 8.2. Cold Symptoms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Cough Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTITUSSIVE DRUGS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Product Type
• 9.2. Over-The-counter (OTC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Prescription Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTITUSSIVE DRUGS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Age Group
• 10.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ANTITUSSIVE DRUGS MARKET: BY END-USERS 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast End-users
• 11.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 12.1. Market Analysis, Insights and Forecast Distribution Channel
• 12.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 13. GLOBAL ANTITUSSIVE DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 13.1. Regional Outlook
• 13.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.2.1 By Drug
  • 13.2.2 By Drug Class
  • 13.2.3 By Route Of Administration
  • 13.2.4 By Dosage Form
  • 13.2.5 By Indication
  • 13.2.6 By Product Type
  • 13.2.7 By Age Group
  • 13.2.8 By End-users
  • 13.2.9 By Distribution Channel
  • 13.2.10 United States
  • 13.2.11 Canada
  • 13.2.12 Mexico
• 13.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.3.1 By Drug
  • 13.3.2 By Drug Class
  • 13.3.3 By Route Of Administration
  • 13.3.4 By Dosage Form
  • 13.3.5 By Indication
  • 13.3.6 By Product Type
  • 13.3.7 By Age Group
  • 13.3.8 By End-users
  • 13.3.9 By Distribution Channel
  • 13.3.10 United Kingdom
  • 13.3.11 France
  • 13.3.12 Germany
  • 13.3.13 Italy
  • 13.3.14 Russia
  • 13.3.15 Rest Of Europe
• 13.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.4.1 By Drug
  • 13.4.2 By Drug Class
  • 13.4.3 By Route Of Administration
  • 13.4.4 By Dosage Form
  • 13.4.5 By Indication
  • 13.4.6 By Product Type
  • 13.4.7 By Age Group
  • 13.4.8 By End-users
  • 13.4.9 By Distribution Channel
  • 13.4.10 India
  • 13.4.11 Japan
  • 13.4.12 South Korea
  • 13.4.13 Australia
  • 13.4.14 South East Asia
  • 13.4.15 Rest Of Asia Pacific
• 13.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.5.1 By Drug
  • 13.5.2 By Drug Class
  • 13.5.3 By Route Of Administration
  • 13.5.4 By Dosage Form
  • 13.5.5 By Indication
  • 13.5.6 By Product Type
  • 13.5.7 By Age Group
  • 13.5.8 By End-users
  • 13.5.9 By Distribution Channel
  • 13.5.10 Brazil
  • 13.5.11 Argentina
  • 13.5.12 Peru
  • 13.5.13 Chile
  • 13.5.14 Rest of Latin America
• 13.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.6.1 By Drug
  • 13.6.2 By Drug Class
  • 13.6.3 By Route Of Administration
  • 13.6.4 By Dosage Form
  • 13.6.5 By Indication
  • 13.6.6 By Product Type
  • 13.6.7 By Age Group
  • 13.6.8 By End-users
  • 13.6.9 By Distribution Channel
  • 13.6.10 Saudi Arabia
  • 13.6.11 UAE
  • 13.6.12 Israel
  • 13.6.13 South Africa
  • 13.6.14 Rest of the Middle East And Africa

Chapter 14. COMPETITIVE LANDSCAPE

• 14.1. Recent Developments
• 14.2. Company Categorization
• 14.3. Supply Chain & Channel Partners (based on availability)
• 14.4. Market Share & Positioning Analysis (based on availability)
• 14.5. Vendor Landscape (based on availability)
• 14.6. Strategy Mapping

Chapter 15. COMPANY PROFILES OF GLOBAL ANTITUSSIVE DRUGS INDUSTRY

• 15.1. Top Companies Market Share Analysis
• 15.2. Company Profiles
  • 15.2.1 F. Hoffmann-La Roche Ltd
  • 15.2.2 Pfizer Inc
  • 15.2.3 Novartis AG
  • 15.2.4 GlaxoSmithKline Plc
  • 15.2.5 Sanofi
  • 15.2.6 Johnson & Johnson Private Limited
  • 15.2.7 Teva Pharmaceutical Industries Ltd
  • 15.2.8 Sun Pharmaceutical Industries Ltd
  • 15.2.9 Mylan N.V
  • 15.2.10 AstraZeneca
  • 15.2.11 Bayer AG
  • 15.2.12 Cipla Inc
  • 15.2.13 Aurobindo Pharma
  • 15.2.14 Hikma Pharmaceuticals PLC
  • 15.2.15 Amneal Pharmaceuticals LLC